Durgadevi Parthasarathy

Durgadevi Parthasarathy

Auto-generated profile, based on publicly available information

Durgadevi Parthasarathy

Medical School United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDurgadevi Parthasarathy
Durgadevi Parthasarathy
KPKarunakar Reddy Pothula
Karunakar Reddy Pothula
SRSneha Ratnapriya
Sneha Ratnapriya
HBHéctor Cervera Benet
Héctor Cervera Benet
RPRuth Parsons
Ruth Parsons
AHAlon Herschhorn
Alon Herschhorn
HIV-1 envelope glycoproteins (Envs) of most primary HIV-1 strains exist in closed conformation and infrequently sample open states, limiting access to internal epitopes. Thus, immunogen design aims to mimic the closed Env conformation as preferred target for eliciting broadly neutralizing antibodies (bnAbs). Here we identify incompletely closed Env conformations of 6 out of 13 transmitted/founder (T/F) strains that are sensitive to antibodies that recognize internal epitopes typically exposed on open Envs. A 3.6 Å cryo-electron microscopy structure of unliganded, incompletely closed T/F Envs (1059-SOSIP) reveals protomer motion that increased sampling of states with incompletely closed trimer apex. We reconstruct de novo the post-transmission evolutionary pathway of a second T/F. Evolved viruses exhibit increased Env resistance to cold, soluble CD4 and 19b, all of which correlate with closing of the adapted Env trimer. Lastly, we show that the ultra-broad N6 bnAb efficiently recognizes different Env conformations and exhibits improved antiviral breadth against VRC01-resistant Envs isolated during the first-in-humans antibody-mediated-prevention trial.

15 September 2024 in Indian Journal of Microbiology Research
Verified
Journal Article
Open access
PDF file
LMLakshmipathy Meena
Lakshmipathy Meena
KSKrishnan Selvi
Krishnan Selvi
AKA. V. Kavitha
A. V. Kavitha
SASunderesan Anand
Sunderesan Anand
DPDurgadevi Parthasarathy
Durgadevi Parthasarathy
The aim of this study was to compare the Minimum Inhibitory Concentration (MIC) and Mutant Prevention Concentration (MPC) of fluoroquinolones, including ciprofloxacin, moxifloxacin, and gatifloxacin, against and coagulase-negative Staphylococci (CONS) isolated from conjunctival swabs.25 isolates of spp., obtained from conjunctival swabs submitted to the Department of Microbiology, Vision Research Foundation, Sankara Nethralaya, were included in this study. The identification and confirmation of spp. were performed using standard microbiological techniques. The MIC and MPC were determined using the agar dilution method, following protocols from previous studies. The MIC, MIC, MPC, and MPC values for the above three fluoroquinolones were calculated and analysed.Out of all 25 isolates, 20 were CONS and 5 were . In our study, gatifloxacin had least MIC and MPC values when compared to ciprofloxacin and moxifloxacin. of gatifloxacin had lower MPCand MPC values in comparison to ciprofloxacin and moxifloxacin. Our study shows that Gatifloxacin had least MIC and MPC values when compared to ciprofloxacin and moxifloxacin. Besides, MPC of ciprofloxacin, moxifloxacin and gatifloxacin showed wider range of distribution than the MIC.Gatifloxacin demonstrated effective inhibition of resistant mutant strains at lower concentrations compared to ciprofloxacin and moxifloxacin. Additionally, future studies with a larger number of isolates, incorporating pharmacokinetic and pharmacodynamic parameters, will provide essential information on therapeutic outcomes and resistance prevention.